Amyloidosis Stocks List

Amyloidosis Stocks Recent News

Date Stock Title
May 7 IONS Ionis Pharmaceuticals, Inc. (IONS) Q1 2024 Earnings Call Transcript
May 7 ABOS Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024
May 7 IONS Ionis Pharmaceuticals (IONS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
May 7 ALZN Alzamend Neuro terminates at-the-market equity offering program
May 7 IONS Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Misses Revenue Estimates
May 7 ALZN Alzamend Neuro Announces Termination of At-the-Market Equity Offering Program
May 7 ALNY Alnylam Issues 2023 Corporate Responsibility Report
May 7 IONS Ionis Pharmaceuticals GAAP EPS of -$0.98 beats by $0.09, revenue of $119M misses by $17.41M
May 7 IONS Ionis reports first quarter 2024 financial results
May 6 IONS Ionis Pharmaceuticals Q1 2024 Earnings Preview
May 6 IONS Wall Street's Insights Into Key Metrics Ahead of Ionis Pharmaceuticals (IONS) Q1 Earnings
May 5 ALNY The Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) First-Quarter Results Are Out And Analysts Have Published New Forecasts
May 4 BBIO What You Need To Know About The BridgeBio Pharma, Inc. (NASDAQ:BBIO) Analyst Downgrade Today
May 3 NTLA Why Intellia Therapeutics, Inc. (NTLA) Outpaced the Stock Market Today
May 3 ALNY Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q1 2024 Earnings Call Transcript
May 3 GMAB Genmab A/S (NASDAQ:GMAB) Q1 2024 Earnings Call Transcript
May 3 ALNY Alnylam (ALNY) Q1 Loss Narrower Than Expected, Sales Rise Y/Y
May 3 ABUS Arbutus Biopharma Corporation (NASDAQ:ABUS) Q1 2024 Earnings Call Transcript
May 3 NTLA IGM Biosciences, Inc. (IGMS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
May 3 ALNY Alnylam Pharmaceuticals First Quarter 2024 Earnings: Beats Expectations
Amyloidosis

Amyloidosis is a disease in which abnormal proteins, known as amyloid fibrils, build up in tissue. There are several types with varying symptoms; signs and symptoms may include diarrhea, weight loss, feeling tired, enlargement of the tongue, bleeding, numbness, feeling faint with standing, swelling of the legs, or enlargement of the spleen.There are about 30 different types of amyloidosis, each due to a specific protein misfolding. Some are genetic while others are acquired. They are grouped into localized forms, and systemic ones. The four most common types of systemic amyloidosis are light chain (AL), inflammation (AA), dialysis-related (Aβ2M), and hereditary and old age (ATTR and familial amyloid polyneuropathy).Diagnosis may be suspected when protein is found in the urine, organ enlargement is present, or problems are found with multiple peripheral nerves and it is unclear why. Diagnosis is confirmed by tissue biopsy. Due to the variable presentation, a diagnosis can often take some time to reach.Treatment is geared towards decreasing the amount of the involved protein. This may sometimes be achieved by determining and treating the underlying cause. AL amyloidosis occurs in about 3–13 per million people per year and AA amyloidosis in about 2 per million people per year. The usual age of onset of these two types is 55 to 60 years old. Without treatment, life expectancy is between six months and four years. In the developed world about 1 per 1,000 people die from amyloidosis. Amyloidosis has been described since at least 1639.

Browse All Tags